Skip to content
Screener

Kymera Therapeutics KYMR Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$2.9MMiss by $12.2M
EPS-$0.97Miss by $0.19
Revenue estimate$15.0M
EPS estimate-$0.78

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$3.3M
EPS estimate-$1.25

Financials

Q4 2025

Income statement

See full
Revenue$2.9M-61.2%
Operating income-$97.9M-21.2%
Net income-$87.0M-22.9%
EPS (diluted)-$0.98-10.1%

Balance sheet

See full
Cash & equivalents$357.0M+197%
Total debt$84.1M-5.8%
Total equity$1.6B+89.0%
Total assets$1.7B+78.2%

Cash flow

See full
Operating cash flow-$66.7M-8.0%
CapEx$106.0K-88.7%
Free cash flow-$66.9M-6.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$6.22B+139%
Enterprise value$5.95B+131%
P/S158.8×+103×

Profitability

See full
Operating margin-891.1%+1,355pp
Net margin-794.1%+1,610pp
FCF margin-597.7%+332pp

Returns & leverage

See full
Return on equity-25.8%-5.8pp
Debt / equity0.1×-0.1×
Current ratio10.5×+2.9×

FAQ

When did Kymera Therapeutics report Q4 2025 earnings?
Kymera Therapeutics (KYMR) reported Q4 2025 earnings on February 26, 2026 before market open.
What were Kymera Therapeutics's Q4 2025 revenue and EPS?
Kymera Therapeutics reported revenue of $2.9M and eps of $-0.97 for Q4 2025.
Did Kymera Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $15.0M by $12.2M. EPS missed the consensus estimate of $-0.78 by $0.19.
How did Kymera Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 61.2% from $7.4M a year earlier and eps declined 10.2% from $-0.88.
Where can I find Kymera Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-073386) and the 10-K periodic report (0001193125-26-073395) directly on SEC EDGAR. The filing index links above go to sec.gov.